To a big extent, drug development is a crapshoot. Despite all of the research that goes into the products before they even begin clinical trials, no one really knows what's going to happen once a drug company starts using the drug in humans. This unpredictability makes investing in small biotechs very risky. If the company is resting its hopes on a single experimental drug and it bombs, then the stock gets knocked out, too.
This is why broad portfolios of experimental drugs are superior to thin pipelines. A company with a deep drug pipeline is not sunk if one of its drugs fails. To take an optimist's view, a deep pipeline also gives the company a chance to score multiple successes.
Biotech investors should consider taking a look at Motley Fool Rule Breakers recommendation Protein Design Labs
Management initially wanted Nuvion on the market by the end of 2007, but that time frame doesn't seem likely now. PDL has to run two phase 3 trials to get approval from the Food and Drug Administration. Although the first trial starts late this year, the second won't get moving until there's enough data out of the first trial to show that the drug is safe, and that makes it very hard to estimate exactly when Nuvion could launch. Some clarity will come at the end of this month when management is set to discuss the development timeline.
After Nuvion, the PDL drug to watch is its anti-angiogenesis drug M200, which is similar to Genentech's
M200 also stops the formation of blood vessels to tumors, but by a different mechanism from what Avastin uses. It is too early to know whether M200 even works in treating patients. But we might know within the next year whether it will be a blockbuster or a bust, when data from some of the current phase 2 trials will be reported at the 2006 American Society of Clinical Oncology meeting. Along with Nuvion, this is the drug to track over the next 18 months.
For additional articles on the biotech industry, see:
- Thanks for the Ride, Transkaryotic
- A Biotech Value Play
- Has Elan Been KO'd?
- Pfizer Pfaces Its Pfuture
- The Best Company I've Never Owned
Interested in biotechnology? Our Motley Fool Rule Breakers newsletter focuses on biotech and other exciting growth areas. You can take a no-obligation free trial to learn more.
More from The Motley Fool
3 Times Netflix CEO Reed Hastings Predicted the Future
At a time of increasing competition, Hastings' ability to keep his company one step ahead of the competition could become even more valuable.
As Expected, Amazon and Google Dominated the Smart Speaker Market Last Quarter
The smart speaker market is going to heat up in 2018.
4 Holiday Gifts You Can Give Your Career
And, no, we don't mean a stress ball or a new work outfit.